|
1
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weller M and Le Rhun E: How did lomustine
become standard of care in recurrent glioblastoma? Cancer Treat
Rev. 87:1020292020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duffau H and Taillandier L: New concepts
in the management of diffuse low-grade glioma: Proposal of a
multistage and individualized therapeutic approach. Neuro Oncol.
17:332–342. 2015.
|
|
4
|
Campian J and Gutmann DH: CNS tumors in
neurofibromatosis. J Clin Oncol. 35:2378–2385. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lapointe S, Perry A and Butowski NA:
Primary brain tumours in adults. Lancet. 392:432–446. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin L, Cai J and Jiang C: Recent advances
in targeted therapy for glioma. Curr Med Chem. 24:1365–1381. 2017.
View Article : Google Scholar
|
|
7
|
Gottesman MM, Robey RW and Ambudkar SV:
New mechanisms of multidrug resistance: An introduction to the
cancer drug resistance special collection. Cancer Drug Resist.
6:590–595. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu A, Jiang B, Song C, Zhong Q, Mo Y,
Yang R, Chen C, Peng C, Peng F and Tang H: Isoliquiritigenin
inhibits circ0030018 to suppress glioma tumorigenesis via the
miR-1236/HER2 signaling pathway. MedComm (2020).
4:e2822023.PubMed/NCBI
|
|
9
|
Tang H, Liu Q, Liu X, Ye F, Xie X, Xie X
and Wu M: Plasma miR-185 as a predictive biomarker for prognosis of
malignant glioma. J Cancer Res Ther. 11:630–634. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu Q, Fu W, Fu Y, Ye W, Yan H, Yu Z, Li R,
Cai Y, Chen Y, Wang L, et al: BNIP3 as a potential biomarker for
the identification of prognosis and diagnosis in solid tumours. Mol
Cancer. 22:1432023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang B, Zhao J, Wang Y, Xu H, Gao BO,
Zhang G, Han B, Song G, Zhang J and Meng W: CHRM3 is a novel
prognostic factor of poor prognosis and promotes glioblastoma
progression via activation of oncogenic invasive growth factors.
Oncol Res. 31:917–927. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cordaux R and Batzer MA: The impact of
retrotransposons on human genome evolution. Nat Rev Genet.
10:691–703. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Smit AF: Interspersed repeats and other
mementos of transposable elements in mammalian genomes. Curr Opin
Genet Dev. 9:657–663. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Muñoz-López M and García-Pérez JL: DNA
transposons: Nature and applications in genomics. Curr Genomics.
11:115–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schrader L and Schmitz J: The impact of
transposable elements in adaptive evolution. Mol Ecol.
28:1537–1549. 2019. View Article : Google Scholar
|
|
16
|
Percharde M, Sultana T and Ramalho-Santos
M: What doesn't kill you makes you stronger: Transposons as dual
players in chromatin regulation and genomic variation. Bioessays.
42:e19002322020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morales ME, Servant G, Ade C and Roy-Engel
AM: Altering genomic integrity: Heavy metal exposure promotes
transposable element-mediated damage. Biol Trace Elem Res.
166:24–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deniz Ö, Frost JM and Branco MR:
Regulation of transposable elements by DNA modifications. Nat Rev
Genet. 20:417–431. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saleh A, Macia A and Muotri AR:
Transposable elements, inflammation, and neurological disease.
Front Neurol. 10:8942019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Burns KH: Our conflict with transposable
elements and its implications for human disease. Annu Rev Pathol.
15:51–70. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Payer LM and Burns KH: Transposable
elements in human genetic disease. Nat Rev Genet. 20:760–772. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yusa K: piggyBac transposon. Microbiol
Spectr. 3:MDNA3-0028-20142015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Helou L, Beauclair L, Dardente H, Piégu B,
Tsakou-Ngouafo L, Lecomte T, Kentsis A, Pontarotti P and Bigot Y:
The piggyBac-derived protein 5 (PGBD5) transposes both the closely
and the distantly related piggyBac-like elements Tcr-pble and Ifp2.
J Mol Biol. 433:1668392021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Majumdar S, Singh A and Rio DC: The human
THAP9 gene encodes an active P-element DNA transposase. Science.
339:446–448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Henssen AG, Henaff E, Jiang E, Eisenberg
AR, Carson JR, Villasante CM, Ray M, Still E, Burns M, Gandara J,
et al: Genomic DNA transposition induced by human PGBD5. Elife.
4:e105652015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pavelitz T, Gray LT, Padilla SL, Bailey AD
and Weiner AM: PGBD5: A neural-specific intron-containing piggyBac
transposase domesticated over 500 million years ago and conserved
from cephalochordates to humans. Mob DNA. 4:232013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sarkar A, Sim C, Hong YS, Hogan JR, Fraser
MJ, Robertson HM and Collins FH: Molecular evolutionary analysis of
the wide-spread piggyBac transposon family and related
'domesticated' sequences. Mol Genet Genomics. 270:173–180. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Henssen AG, Koche R, Zhuang J, Jiang E,
Reed C, Eisenberg A, Still E, MacArthur IC, Rodríguez-Fos E,
Gonzalez S, et al: PGBD5 promotes site-specific oncogenic mutations
in human tumors. Nat Genet. 49:1005–1014. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xie W, Zeng Y, Hu L, Hao J, Chen Y, Yun X,
Lin Q and Li H: Based on different immune responses under the
glucose metabolizing type of papillary thyroid cancer and the
response to anti-PD-1 therapy. Front Immunol. 13:9916562022.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu Z, Du M and Lu L: A novel 16-genes
signature scoring system as prognostic model to evaluate survival
risk in patients with glioblastoma. Biomedicines. 10:3172022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Phua WWT, Wong MXY, Liao Z and Tan NS: An
aPPARent functional consequence in skeletal muscle physiology via
peroxisome proliferator-activated receptors. Int J Mol Sci.
19:14252018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Montaigne D, Butruille L and Staels B:
PPAR control of metabolism and cardiovascular functions. Nat Rev
Cardiol. 18:809–823. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang YX: PPARs: Diverse regulators in
energy metabolism and metabolic diseases. Cell Res. 20:124–137.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mirza AZ, Althagafi II and Shamshad H:
Role of PPAR receptor in different diseases and their ligands:
Physiological importance and clinical implications. Eur J Med Chem.
166:502–513. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tan Y, Wang M, Yang K, Chi T, Liao Z and
Wei P: PPAR-alpha modulators as current and potential cancer
treatments. Front Oncol. 11:5999952021. View Article : Google Scholar
|
|
36
|
Dong YW, Wang XP and Wu K: Suppression of
pancreatic carcinoma growth by activating peroxisome
proliferator-activated receptor gamma involves angiogenesis
inhibition. World J Gastroenterol. 15:441–448. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang N, Li G, Li X, Xu L and Chen M:
Circ5379-6, a circular form of tumor suppressor PPARα, participates
in the inhibition of hepatocellular carcinoma tumorigenesis and
metastasis. Am J Transl Res. 10:3493–3503. 2018.
|
|
38
|
Andrejeva D, Kugler JM, Nguyen HT,
Malmendal A, Holm ML, Toft BG, Loya AC and Cohen SM: Metabolic
control of PPAR activity by aldehyde dehydrogenase regulates
invasive cell behavior and predicts survival in hepatocellular and
renal clear cell carcinoma. BMC Cancer. 18:11802018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen SZ, Ling Y, Yu LX, Song YT, Chen XF,
Cao QQ, Yu H, Chen C, Tang JJ, Fan ZC, et al: 4-Phenylbutyric acid
promotes hepatocellular carcinoma via initiating cancer stem cells
through activation of PPAR-α. Clin Transl Med. 11:e3792021.
View Article : Google Scholar
|
|
40
|
Wagner N and Wagner KD: PPAR beta/delta
and the hallmarks of cancer. Cells. 9:11332020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chi T, Wang M, Wang X, Yang K, Xie F, Liao
Z and Wei P: PPAR-γ modulators as current and potential cancer
treatments. Front Oncol. 11:7377762021. View Article : Google Scholar
|
|
42
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
43
|
Li X and Meng Y: Analyses of
metastasis-associated genes in IDH wild-type glioma. BMC Cancer.
20:11142020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang
Z, Dai Z, Zhang X, Zhang L, Peng Y, et al: Glioma targeted therapy:
Insight into future of molecular approaches. Mol Cancer. 21:392022.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Christofides A, Konstantinidou E, Jani C
and Boussiotis VA: The role of peroxisome proliferator-activated
receptors (PPAR) in immune responses. Metabolism. 114:1543382021.
View Article : Google Scholar
|
|
46
|
Xi Y, Zhang Y, Zhu S, Luo Y, Xu P and
Huang Z: PPAR-mediated toxicology and applied pharmacology. Cells.
9:3522020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jimenez R, Toral M, Gómez-Guzmán M, Romero
M, Sanchez M, Mahmoud AM and Duarte J: The role of Nrf2 signaling
in PPARβ/δ-mediated vascular protection against
hyperglycemia-induced oxidative stress. Oxid Med Cell Longev.
2018:58527062018. View Article : Google Scholar
|
|
48
|
Botta M, Audano M, Sahebkar A, Sirtori CR,
Mitro N and Ruscica M: PPAR agonists and metabolic syndrome: An
established role? Int J Mol Sci. 19:11972018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cheng HS, Tan WR, Low ZS, Marvalim C, Lee
JYH and Tan NS: Exploration and development of PPAR modulators in
health and disease: An update of clinical evidence. Int J Mol Sci.
20:50552019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Heudobler D, Rechenmacher M, Lüke F,
Vogelhuber M, Pukrop T, Herr W, Ghibelli L, Gerner C and Reichle A:
Peroxisome proliferator-activated receptors (PPAR)γ agonists as
master modulators of tumor tissue. Int J Mol Sci. 19:35402018.
View Article : Google Scholar
|
|
51
|
Wang W, Wang R, Zhang Z, Li D and Yut Y:
Enhanced PPAR-gamma expression may correlate with the development
of Barrett's esophagus and esophageal adenocarcinoma. Oncol Res.
19:141–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Feige JN, Gelman L, Michalik L, Desvergne
B and Wahli W: From molecular action to physiological outputs:
Peroxisome proliferator-activated receptors are nuclear receptors
at the crossroads of key cellular functions. Prog Lipid Res.
45:120–159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Braissant O, Foufelle F, Scotto C, Dauça M
and Wahli W: Differential expression of peroxisome
proliferator-activated receptors (PPARs): Tissue distribution of
PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology.
137:354–366. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Peters JM, Lee SS, Li W, Ward JM,
Gavrilova O, Everett C, Reitman ML, Hudson LD and Gonzalez FJ:
Growth, adipose, brain, and skin alterations resulting from
targeted disruption of the mouse peroxisome proliferator-activated
receptor beta(delta). Mol Cell Biol. 20:5119–5128. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bhullar KS and Rupasinghe HP: Polyphenols:
Multipotent therapeutic agents in neurodegenerative diseases. Oxid
Med Cell Longev. 2013:8917482013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Altinoz MA, Elmaci I, Hacimuftuoglu A and
Ozpinar A, Hacker E and Ozpinar A: PPARδ and its ligand erucic acid
may act anti-tumoral, neuroprotective, and myelin protective in
neuroblastoma, glioblastoma, and Parkinson's disease. Mol Aspects
Med. 78:1008712021. View Article : Google Scholar
|
|
57
|
Altinoz MA, Bilir A and Elmaci I: Erucic
acid, a component of Lorenzo's oil and PPAR-δ ligand modifies C6
glioma growth and toxicity of doxorubicin. Experimental data and a
comprehensive literature analysis. Chem Biol Interact. 294:107–117.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Leisewitz AV, Urrutia CR, Martinez GR,
Loyola G and Bronfman M: A PPARs cross-talk concertedly commits C6
glioma cells to oligodendrocytes and induces enzymes involved in
myelin synthesis. J Cell Physiol. 217:367–376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Seufert S, Coras R, Tränkle C, Zlotos DP,
Blümcke I, Tatenhorst L, Heneka MT and Hahnen E: PPAR gamma
activators: Off-target against glioma cell migration and brain
invasion. PPAR Res. 2008:5139432008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Khoo NKH, Hebbar S, Zhao W, Moore SA,
Domann FE and Robbins ME: Differential activation of catalase
expression and activity by PPAR agonists: Implications for
astrocyte protection in anti-glioma therapy. Redox Biol. 1:70–79.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang X, Wang G, Shi Y, Sun L, Gorczynski
R, Li YJ, Xu Z and Spaner DE: PPAR-delta promotes survival of
breast cancer cells in harsh metabolic conditions. Oncogenesis.
5:e2322016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang J, Yang W, Zhao D, Han Y, Liu B,
Zhao H, Wang H, Zhang Q and Xu G: Correlation between TSP-1, TGF-β
and PPAR-γ expression levels and glioma microvascular density.
Oncol Lett. 7:95–100. 2014. View Article : Google Scholar
|
|
63
|
Kolacsek O, Wachtl G, Fóthi Á, Schamberger
A, Sándor S, Pergel E, Varga N, Raskó T, Izsvák Z, Apáti Á and
Orbán TI: Functional indications for transposase
domestications-characterization of the human piggyBac transposase
derived (PGBD) activities. Gene. 834:1466092022. View Article : Google Scholar
|
